Answers are grounded in this paper and cite their sources.
FSP neoantigen vaccination is systemically well tolerated and consistently induces humoral and cellular immune responses, thus representing a promising novel approach for treatment and even prevention of MMR-deficient cancer.
No takes yet. Share an insight, caveat, or question.
Kloor et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: